Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
First Claim
Patent Images
1. An isolated polynucleotide comprising a sequence selected from the group consisting of:
- (a) sequences provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 86;
(b) complements of the sequences provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, and 76-78;
(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87;
(d) sequences that hybridize to a sequence provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 86, under highly stringent conditions;
(e) sequences having at least 75% identity to a sequence of SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87;
(f) sequences having at least 90% identity to a sequence of SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87; and
(g) degenerate variants of a sequence provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn'"'"'s Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
-
Citations
72 Claims
-
1. An isolated polynucleotide comprising a sequence selected from the group consisting of:
-
(a) sequences provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 86;
(b) complements of the sequences provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, and 76-78;
(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87;
(d) sequences that hybridize to a sequence provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 86, under highly stringent conditions;
(e) sequences having at least 75% identity to a sequence of SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87;
(f) sequences having at least 90% identity to a sequence of SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87; and
(g) degenerate variants of a sequence provided in SEQ ID NOs;
75, 83, 85, 1-37, 51-74, 76-78 and 87. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)
-
-
53. A method of identifying bacterial antigens associated with inflammatory bowel disease in a first mammal, comprising the steps of:
-
(a) obtaining a biological sample from said first mammal wherein said biological sample comprises DNA from cecal bacteria;
(b) constructing an expression library with said DNA;
(c) screening said expression library with sera from either said first mammal or a second mammal with inflammatory bowel disease;
thereby identifying bacterial antigens associated with inflammatory bowel disease.
-
-
54. The method of 53 wherein said first and said second mammal are both mice.
-
55. The method of 53 wherein said first mammal is a C3H/HeJ Bir mouse and said second mammal is a mouse of a strain selected from the group consisting of BALB/c IL-10−
- /−
, B6 IL-10−
/−
, B10 IL-10 −
/−
, MDR1a −
/−
, TCRα
−
/−
, IL-2 −
/−
, IL-2R −
/−
, mice with DSS (Dextransodiumsulfate) induced colitis, Gα
ai −
/−
, and CD45 RB transgenic mice.
- /−
-
56. The method of 53 wherein said first mammal is a mouse and said second mammal is a human.
Specification